Accepted
at 3:13 p.m. Oct, 07, 2023
by
TheAnKing
Author:
jaynguyen
Type of change:
Updated Tags
Rationale for change
This section was signifiantly revised in 2nd gen alikhan. I have made new cards for this section. Would consider deleting this card
No changes in fields
Text
{{c1::PD-1 inhibitors (pembrolizumab, nivolumab)}} have quickly become the preferred approach to immunotherapy for advanced melanoma over ipilimumab since they are more effective and have fewer side effects
Extra
PD-1 is an immune checkpoint receptor expressed by activated T-cells. It normally functions as a "brake" on the immune response.
PD-1 on activated T-cells binds to its ligands PD1-L1 (B7-H1) and PD1-L2 (B7-DC), which are expressed on tumor cells causing deactivation of T-cells and loss of immune response against tumor
PD-1 on activated T-cells binds to its ligands PD1-L1 (B7-H1) and PD1-L2 (B7-DC), which are expressed on tumor cells causing deactivation of T-cells and loss of immune response against tumor
Personal Notes
Empty field
Missed Questions
Empty field
DermPath
Empty field
Dermoscopy
Empty field
VisualDx
Empty field
DermNet
Empty field
Full Spectrum of Dermatology
Empty field
Dermnemonics
Empty field
Dermatographix
Empty field
Textbook
Empty field
Additional Resources
Empty field
One by one
Empty field